The Experts below are selected from a list of 153 Experts worldwide ranked by ideXlab platform
F Soria - One of the best experts on this subject based on the ideXlab platform.
-
comparative sensitivity of urinary cyfra 21 1 urinary bladder cancer Antigen Tissue Polypeptide Antigen and nmp22 to detect bladder cancer
The Journal of Urology, 1999Co-Authors: Marta Sanchezcarbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer Antigen, Tissue Polypeptide Antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer Antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., Tissue Polypeptide Antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer Antigen, 760.8 U./l. for Tissue Polypeptide Antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer Antigen quantitative and 80.2% for Tissue Polypeptide Antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer Antigen and 36% for Tissue Polypeptide Antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer Antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
-
COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER Antigen, Tissue Polypeptide Antigen AND NMP22 * TO DETECT BLADDER CANCER
The Journal of urology, 1999Co-Authors: Marta Sanchez-carbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer Antigen, Tissue Polypeptide Antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer Antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., Tissue Polypeptide Antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer Antigen, 760.8 U./l. for Tissue Polypeptide Antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer Antigen quantitative and 80.2% for Tissue Polypeptide Antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer Antigen and 36% for Tissue Polypeptide Antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer Antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
Enrique Herrero - One of the best experts on this subject based on the ideXlab platform.
-
comparative sensitivity of urinary cyfra 21 1 urinary bladder cancer Antigen Tissue Polypeptide Antigen and nmp22 to detect bladder cancer
The Journal of Urology, 1999Co-Authors: Marta Sanchezcarbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer Antigen, Tissue Polypeptide Antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer Antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., Tissue Polypeptide Antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer Antigen, 760.8 U./l. for Tissue Polypeptide Antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer Antigen quantitative and 80.2% for Tissue Polypeptide Antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer Antigen and 36% for Tissue Polypeptide Antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer Antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
-
COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER Antigen, Tissue Polypeptide Antigen AND NMP22 * TO DETECT BLADDER CANCER
The Journal of urology, 1999Co-Authors: Marta Sanchez-carbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer Antigen, Tissue Polypeptide Antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer Antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., Tissue Polypeptide Antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer Antigen, 760.8 U./l. for Tissue Polypeptide Antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer Antigen quantitative and 80.2% for Tissue Polypeptide Antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer Antigen and 36% for Tissue Polypeptide Antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer Antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
Antonio Mira - One of the best experts on this subject based on the ideXlab platform.
-
comparative sensitivity of urinary cyfra 21 1 urinary bladder cancer Antigen Tissue Polypeptide Antigen and nmp22 to detect bladder cancer
The Journal of Urology, 1999Co-Authors: Marta Sanchezcarbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer Antigen, Tissue Polypeptide Antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer Antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., Tissue Polypeptide Antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer Antigen, 760.8 U./l. for Tissue Polypeptide Antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer Antigen quantitative and 80.2% for Tissue Polypeptide Antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer Antigen and 36% for Tissue Polypeptide Antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer Antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
-
COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER Antigen, Tissue Polypeptide Antigen AND NMP22 * TO DETECT BLADDER CANCER
The Journal of urology, 1999Co-Authors: Marta Sanchez-carbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer Antigen, Tissue Polypeptide Antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer Antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., Tissue Polypeptide Antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer Antigen, 760.8 U./l. for Tissue Polypeptide Antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer Antigen quantitative and 80.2% for Tissue Polypeptide Antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer Antigen and 36% for Tissue Polypeptide Antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer Antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
Julian Megias - One of the best experts on this subject based on the ideXlab platform.
-
comparative sensitivity of urinary cyfra 21 1 urinary bladder cancer Antigen Tissue Polypeptide Antigen and nmp22 to detect bladder cancer
The Journal of Urology, 1999Co-Authors: Marta Sanchezcarbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer Antigen, Tissue Polypeptide Antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer Antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., Tissue Polypeptide Antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer Antigen, 760.8 U./l. for Tissue Polypeptide Antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer Antigen quantitative and 80.2% for Tissue Polypeptide Antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer Antigen and 36% for Tissue Polypeptide Antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer Antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
-
COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER Antigen, Tissue Polypeptide Antigen AND NMP22 * TO DETECT BLADDER CANCER
The Journal of urology, 1999Co-Authors: Marta Sanchez-carbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer Antigen, Tissue Polypeptide Antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer Antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., Tissue Polypeptide Antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer Antigen, 760.8 U./l. for Tissue Polypeptide Antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer Antigen quantitative and 80.2% for Tissue Polypeptide Antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer Antigen and 36% for Tissue Polypeptide Antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer Antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
Marta Sanchez-carbayo - One of the best experts on this subject based on the ideXlab platform.
-
COMPARATIVE SENSITIVITY OF URINARY CYFRA 21-1, URINARY BLADDER CANCER Antigen, Tissue Polypeptide Antigen AND NMP22 * TO DETECT BLADDER CANCER
The Journal of urology, 1999Co-Authors: Marta Sanchez-carbayo, Enrique Herrero, Julian Megias, Antonio Mira, F SoriaAbstract:Purpose: We compare the individual and combined sensitivity of urinary CYFRA 21-1, urinary bladder cancer Antigen, Tissue Polypeptide Antigen and NMP22 to detect bladder cancer, evaluate the false-positive rates for different pathological conditions, and assess differential sensitivity regarding histological and clinical characteristics of disease. Materials and Methods: A total of 267 subjects entered the study. Sensitivities of the tests were evaluated in 111 patients with active bladder cancer and 76 with no evidence of disease. False-positive rates were evaluated in 80 symptomatic and asymptomatic controls, including patients with benign urological conditions and nonbladder malignancies, and healthy subjects. CYFRA 21-1 was determined by electrochemoluminescent immunoassay in the Elecsys 2010,* urinary bladder cancer Antigen was quantified by enzyme linked immunosorbent assay (IDL Biotech) † †IDL Biotech, Sollentuna, Sweden., Tissue Polypeptide Antigen was measured by the Prolifigen TPA-IRMA ‡ ‡Sangtec Medical, Bromma, Sweden. and NMP22 was assayed by enzyme linked immunosorbent assay (Matritech). Cutoffs were obtained by the 95% percentile in patients with no evidence of disease, which gave a 95% specificity for all biomarkers. Differences in sensitivity of urinary biomarkers regarding stage, grade, tumor size, pattern of growth, focality and recurrence were evaluated. Results: At a specificity of 95% cutoffs were 5.4 ng./ml. for CYFRA 21-1, 15.5 μg./l. for urinary bladder cancer Antigen, 760.8 U./l. for Tissue Polypeptide Antigen and 14.6 U./ml. for NMP22. Using these cutoffs sensitivities were 75.7% for NMP22, 83.8% for CYFRA 21-1, 73.9% for urinary bladder cancer Antigen quantitative and 80.2% for Tissue Polypeptide Antigen. The additional determination of cytokeratins increased the sensitivity of NMP22. Cytokeratins did not appear to be specific for bladder cancer, and false-positives rates were between 20% for urinary bladder cancer Antigen and 36% for Tissue Polypeptide Antigen for benign urological conditions, and between 40% and 52%, respectively, for nonbladder malignancies. NMP22 showed lower false-positives rates, mainly for benign diseases. Urinary tumor markers appeared to be associated with some of the most relevant histological and clinical parameters of bladder cancer. Conclusions: Our preliminary evaluation showed the tests to be potential noninvasive adjuncts to help determine the need for cystoscopy. The combination of 2 tumor markers, NMP22 and 1 cytokeratin (CYFRA 21-1 or urinary bladder cancer Antigen), seemed to be the most effective. Further comparative studies are needed to assess the promising diagnostic role of these markers.
